Erste Asset Management’s Apogee Therapeutics APGE Stock Holding History

Erste Asset Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.18M	Hold	24,000	–	–	0.02%	333
2026 Q1	$1.89M	Hold	24,000	–	–	0.02%	371
2025 Q4	$1.83M	Hold	24,000	–	–	0.02%	360
2025 Q3	$956K	Hold	24,000	–	–	0.01%	418
2025 Q2	$1.04M	Hold	24,000	–	–	0.01%	498
2025 Q1	$953K	Hold	24,000	–	–	0.01%	381
2024 Q4	$1.1M	Buy	+24,000	New	+$1.22M	0.01%	373

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Erste Asset Management's APGE Position: Q2 2026 in Review

Erste Asset Management held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 24,000 shares worth $3.18M. The position accounts for 0.02% of the portfolio, ranked #333.

Erste Asset Management first reported a position in APGE in Q4 2024 and has held it in 7 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Erste Asset Management held 24,000 shares of Apogee Therapeutics worth $3.18M as of Q2 2026.
Erste Asset Management left its Apogee Therapeutics share count unchanged in Q2 2026.
Apogee Therapeutics made up 0.02% of Erste Asset Management's portfolio in Q2 2026, its #333 holding.
Erste Asset Management first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 7 quarters since.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.